Browsing Tag
American Academy of Dermatology
7 posts
Incyte (NASDAQ: INCY) moves closer to an hidradenitis suppurativa launch as 54-week povorcitinib data hold up
Incyte Corporation’s new 54-week povorcitinib data could reshape hidradenitis suppurativa treatment. Read what it means for INCY now.
Takeda (NYSE: TAK) boosts psoriasis ambitions as Phase 3 zasocitinib data sharpen oral TYK2 challenge
Takeda’s Phase 3 zasocitinib psoriasis data could reshape the oral TYK2 race. Read what it means for Takeda, rivals, and the market now.
Biocon Biologics reports positive Phase 3 results for Yesintek, biosimilar to Ustekinumab
Biocon Biologics Ltd., a global leader in biosimilar medicines and a subsidiary of India’s pioneering biopharmaceutical giant Biocon…
Torqur AG reports promising Phase 2 results for bimiralisib, full data expected by June
Torqur AG, a biotechnology company specializing in oncology and dermatology treatments, has presented interim Phase 2 clinical trial…
Hoth Therapeutics advances HT-001 as promising therapy for EGFR inhibitor-related skin toxicities
Hoth Therapeutics, Inc. has announced positive findings for HT-001 treatment, positioning it as a potential breakthrough therapy for…
LEO Pharma showcases promising results from DELTA 3 trial at AAD Congress
In a significant development within the field of medical dermatology, LEO Pharma A/S, a global leader renowned for…
UCB announces positive 48-week results for BIMZELX in Hidradenitis Suppurativa studies
At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, UCB, a leading global…